Ruliang Zhang

Department Of R&D
Shanghai, 201203, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy.

IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy.

Journal: Antibody therapeutics

Published: November 14, 2025

Development of bioassay platforms for biopharmaceuticals using Jurkat-CAR cells by AICD.

Development of bioassay platforms for biopharmaceuticals using Jurkat-CAR cells by AICD.

Journal: Journal of pharmaceutical and biomedical analysis

Published: April 11, 2024

IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy.

IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy.

Journal: Heliyon

Published: April 10, 2024

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38.

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38.

Journal: Frontiers in immunology

Published: March 10, 2024

The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling.

The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling.

Journal: Frontiers in oncology

Published: June 14, 2023

IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy.

IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy.

Journal: Antibody therapeutics

Published: June 01, 2023

IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells.

IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells.

Journal: Leukemia

Published: October 30, 2022

SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.

SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.

Journal: Journal of hematology & oncology

Published: September 11, 2022

Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A).

Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A).

Journal: Molecules (Basel, Switzerland)

Published: July 15, 2022

Expression and purification of bioactive high-purity human S100A6 in Escherichia coli.

Expression and purification of bioactive high-purity human S100A6 in Escherichia coli.

Journal: Protein expression and purification

Published: December 14, 2011

Showing 1-10 of 10

Last Updated: 09/26/2026